EXPLORING THE ROLE OF OZEMPIC IN WEIGHT MANAGEMENT FOR DIABETIC PATIENTS AND ITS CORRELATION WITH IMPROVED GLYCAEMIC CONTROL COMPARING TRADITIONAL INSULIN THERAPY

This study aimed to evaluate the effectiveness of Ozempic (semaglutide), a GLP-1 receptor agonist, in weight management and glycaemic control among diabetic patients in Pakistan, compared to traditional insulin therapy. Methodology: A cross-sectional study was conducted from 2021 to 2024 across various private and government hospitals in Pakistan, involving 250 type 2 diabetic patients. The participants were divided into two groups: 125 patients received Ozempic, while 125 were treated with conventional insulin therapy. The primary outcomes measured included HbA1c levels, fasting plasma glucose, body weight, BMI, treatment satisfaction, and quality of life. Results: The Ozempic group demonstrated a significant reduction in HbA1c (-1.4% vs. -0.7%, p<0.001), body weight (-4.8 kg vs. +1.5 kg, p<0.001), and BMI (-1.6 kg/m² vs. +0.5 kg/m², p<0.001) compared to the insulin group. Furthermore, patients treated with Ozempic reported higher treatment satisfaction and improved quality of life. Conclusion: Ozempic presents a superior alternative to traditional insulin therapy for managing type 2 diabetes and associated obesity in Pakistan. It should be considered a first-line treatment to improve patient outcomes and reduce the burden of diabetes-related complications.